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The Contribution of Transplantation to 
Gastroenterologic Knowledge 
THOMAS E. STARZL 
How whole-or~an transplantation came 
to be a clinical discipline has been told else-
where by many of the persons directly in-
volved (I). Although the history of the field 
through 1959 was dominated by the kidney 
(2). the extrarenal vacuum rapidly filled in 
the late 1950s with the development in sev-
eral laboratories of canine transplant 
models with which to study all of the intra-
abdommaJ (Fig. 11- J) and thoracic or~nsK 
EARLY ANIMAL MODELS 
The Liver 
A uziiillry T ranspJ.alllllliDn 
In 1955. C. Stuan Welch of Albany. New 
York. described the ansenton of an extra 
!auxiliary) camne liver mto the pelvis or 
right paravenebral gulter of nommmuno-
suppressed recipients (3), The aUogrart he-
patic anery was revascularized from the 
aona or iliac anery. and the ponal now was 
restored by rerouting the high volume sys-
temic venous return of the host anferior vena 
cava anto the !,!ralt ponal vean IFi!,!. 21-21. 
It was not discovered until a decade later 
that factors other than reJcctlon were an-
volved In the rJ.pld destruction of the aUXil-
Iary transplant (sec subsequent secllon on 
hepatotrophic phvsiology I. 
Onh01opic Liver TranspianuUJon 
The first mention oa'liverreplacement lor-
thotoplc transplantatiOn. I ci~K11-PF was by 
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Dr. Jack Cannon of the University of Cali-
fornia. Los Angeles. who cited Welch's ani-
ele as the stimulus for his own "several suc-
cessful" operations in dogs "without 
survival of the pallent" (4). Assuming that 
the liver played an Important role in rejec-
lion. Cannon speculated that the graft 
would not contribute to its own repudiation. 
No details were given about the operation. 
which remaaned vinuaJly unknown until its 
independent investigation in dogs beginmng 
in the summer of 1958 at the Peter Bent 
Brigham Hospital (Boston) 15-7) and at 
Nonhwestern Umverslty (Chicago) US,9). 
The Boston effon under the direction of 
Francis D. Moore was part of an Immuno-
logically oriented institutional commitment 
to organ transplantation that mitially was 
preoccupied with the kidney (10). 
In contrast. the Nonhwestern initiative 
stemmed from a conviction that the liver 
was a modulator of endo~enous Insuiin. or 
Instead was governed by this hormone 
I 11-13), Such metabolic questions and their 
investigation ultimately led to the develop-
ment of a new tield caJled "hepatotrophic 
physiology" / 14.15), To pursue them. a new 
techmque of total hepatectomy Ilhe lirst 
half of a transplant operation, was devel-
llped (16), The second step ot Insenlng an 
allogra!t anto the vacated hepatic fossa soon 
followed: from the outset. the supenor Ii,,-
I!r-supponlnl.! qualities 01 ponal versus sys-
t~mlc venous blood were obVIOUS un. 
Althou2h there was no etTectlve way to 
prevent reJection. an astonlshtn~ amount of 
I 
I 
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information about orthotopic liver trans-
plantation was compiled in 11)58 and 11)59. 
At the April 1960 meeting of the American 
Surgical Association. Moore reported on 31 
I.:anine experiments with 7 survivors of 4 to 
11 days. In discussing his paper (17). 1 de-
'icribed an experience that was in press else-
where t~F with more than 80 dogs. of which 
I M had lived for 4 to 20-1/2 days. Rejection 
was always present after 5 or 6 days and 
Iisualiv was the cause of death thereafter. 
Beyond demonstrating the need to revas-
.:ulanze the hepatic graft with splanchnic 
venous blood. the work in Hoston and Chi-
.:ago daritied the other requirements for 
~uccessful liver replacement. Preservation 
of the transplanted liver was accomplished 
with intraportal infusion of chilled elec-
trolyte solutions In much the same way as 
pracllccd clinically today E~lK Improved 
IOfusates 10 the succeeding years (18.11)) 
Fig. 21-1. The complex of 
intra-abdominal viscera which 
has been transplanted as a unit 
(centerl or as separate compo-
nents. Counterclockwise: u. 
liver: h. pancreas: c. liver-in-
testine: d. intestine: £'. liver-
pancreas. 
~ventually replaced the originally used lac-
tated Ringer's and saline solutions. Until 
11)87. the safe preservation time was only 5 
or 6 hours. but since then. the University of 
Wisconsin (UW) solution t 20) has permitted 
reliable safe refrigeration of human livers 
for Itl to 24 hours 121.22). 
The tinal requirement for success in dogs 
was the use of plasllc external venous by-
passes that passively redirected blood from 
the occluded splanchnic and systemic ve-
nous beds to the superior vena cava during 
the so-called anhepallc stage while rcclpient 
hepatcctomy was performed and the new 
liver was installed t6Jil. Such venous de-
.:ompression was later shown to be expend-
;lble in dogs submllled several weeks in ad-
\ance of transplantation to common bile 
Juct ligation. because of the development 
10 the intenm of decompressing venous col-
laterals (13), Similarly. venous bypasses 
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Fig. 21-2. Auxiliary liver transplantation in a 
dog by a modification of Welch's original tech-
nique. Note that the reconstituted portal blood 
supply is from the distal inferior vena cava. Re-
drawn with permission from Starzl TE. et al.: 
Immunosuppression after experimental and clin-
ical homotransplantation of the liver. Ann Surg 
160:411., 1964. 
ci~K 21-3. Orthotopic liver 
t ransplantauon til ver replace· 
menll. l.3iliarv tract rccon· 
,trucllon I' usuallv With 
..:holedocholC:JUnostomy (to d 
Roux IImbl or tlnset I with a 
-: holedochocholc:dochoslomv. 
which IS ,tented wilh a T tube. 
Reproduced with permISSion 
trom Slarzl TE el ai.: Medical 
pro!!rt:ss: Liver transplanta· 
tlon. N En!!IJ MedJ2J:IOI4. 
I 'JKIJ. 
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were shown to be nonessential in most clini-
cal cases if the operation was performed by 
highly experienced surgeons 1:4.2.5). 
Nevertheless. the introduction of pump-
driven venovenous bypasses in the 1980s. 
first with (25) and then without anticoagula-
tion <26-28). made the operation less stress-
ful in humans. placed it well within the grasp 
of most competent general and vascular sur-
geons. and allowed the systematic training 
of a new generation of liver transplant sur-
geons. 
Multivisceral and Intestinal 
Transplantation 
I so/aled Intestine 
Nearly 90 years ago. Alexis Carrel and 
c.c. Gunthrie performed canine intestinal 
transplantations. Little more was added 
until the similar studies of small bowel 
transplantation in dogs by Richard Lillehei 
of the University of Minnesota (29). who 
replaced the entire small intestine in unmod-
ified recipients except for short segments of 
jejunum and ileum. The graft was preserved 
by immersing it in iced saline. and the blood 
vessels were anastomosed to companion re-
cipient structures in an anatomicallv normal 
way. Although it was later demons'trated in 
Toronto (30). London tOntario) (31), Pitts-
burgh (32). Kiel (33). and Paris (34) that the 
gut could be successfully replaced with long 
surVIval in large animals under immunosup-
pressIOn. the clinical application of this pro-
cedure languished. The first clinical suc-
cesses did not come until the late 1980s 
(35.36), 
M Ullivisceral Transplantation 
The multiple organ allograft in this versa-
tile operation t37) was enVIsioned as a grape 
..:Iuster with a double central stern consisting 
\ If the celiac aXIs and supertor mesenteric 
.Lrtery (Fig. 21-1. center!. In vanattons of 
the operation used clinically nearly 30 vears 
latcr. the grapes. or im.lividual organs. ~ould 
he removed or retained according to the sur-
gical objectives (fig. 21-1. penpherv I. but 
both artenal stem structures were pre-
'icrved tP~!lK The venous oulllow was kept 
intact up to or bevond the liver. 
Two observations were made In the un-
moditied canme multi visceral recIpIents 01 
1959 that have dominated the field of gas-
troenterologic transplantation since then. 
First. rejection of the organs making up the 
composite graft was less severe than that 
seen when the organs were transplanted in-
dividually (39). This tinding was contirmed 
and greatly extended in 1969 by Caine et al. 
(40). who described in pig liver recipients 
the protection of kidney and skin grafts from 
the hepatic donor: these experiments identi-
fied the liver as the "protective" organ. 
Calne's conclusion about hepatic tolerogen-
icity has been contirmed by the Japanese 
surgeon Naoshi Kamada. whose experi-
ments were performed in rats (41). and by 
many others. Most recently. Valdivia et al. 
(42) demonstrated the similar protection of 
hamster heart and skin xenograt"ts in rats by 
simultaneous or prior xenotransplantation 
of a hamster liver. 
The second fundamental issue raised at 
the outset was the specter of graft-versus-
host disease (GVHD) with the multivisceral 
procedure. GVHD was well known in 1960 
from the prior work of Billingham and Brent 
(43) and Trentin (44). but this was associ-
ated almost exclusively with bone marrow 
or splenocyte tnot whole organ) transplan-
tation. Histopathologic cvidence of GVHD 
was found in recipient tissues of our multi-
visceral canine recipients (3<)). who quickly 
Jcyeloped multiple organ failure. Later ex-
rcrtments by Monchik and Russell (45) con-
tirmed the potential threat of GVHD. uSing 
the F I hybrid model in which the parent and 
FI hybrid offspring were donor and reCIpi-
ent rcspectively. However. these studies 
vastly overestimatcd the GVHD threat after 
splanchnic organ transplantation for rca-
,>ons explained in the subsequent section on 
.. Mechanisms of Graft Acceptance." 
The multivisceral operation is not often 
indicated clinically. hut it has spawned 
man v variations dH) and was itself the pro-
-:cdure with which the tirst long survival t >tt 
months) of a functioning human intestinal 
!,!ratt was accomplished (401. 
Pancreas Transplantation 
Transplantation of the pancreas alone has 
110t been conSIdered in these hlstortcal notes 
because this procedurc IS done onlv for cn-
Jocnne ob,ectlves. However. the (tfecl of 
rancrealtc Insulin secretion on the liver IS a 
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vital concern with all gastroenterologic 
transplant procedures (see next section). 
Furthennore. even the transplantation of 
the whole pancreas "alone" implies the 
concomitant engraftment of a segment of 
duodenum which receives exocrine pan-
creatic secretions and with which the pan-
creas shares its blood supply in humans and 
animals (Fig. 21-1 b). Thus. it was not sur-
prising that pancreaticoduodenal grafts 
were used in the first reported acute experi-
ments on pancreas transplantation (47.48). 
When immunosuppression became avail-
able. essentially the same pancreaticoduo-
denal graft was used in dogs (49) and even-
tually in humans (50). 
HEPATOTROPHIC PHYSIOLOGY: 
LIVER A TROPHY AND 
REGENERATION 
The Eck Fistula and Liver 
Transplantation 
C. S. Welch's conclusion that rejection 
was solely responsible for the rapid destruc-
tion of the auxiliary Ii ver graft (3.51) was 
based on an erroneous concept about liver 
physiology that had evolved from nearly HO 
years of research with the experimental pro-
cedure of Eck's tistula (portacaval shunt! in 
dogs. The operation ot can me Eck fistula is 
well known to gastroenterologists. When it 
is performed. blood returning from the pan-
creas. intestines. and other splanchnic vis-
cera by way of the portal vein is diverted 
around the liver instead of through it. Thus. 
the liver. which now is supplied only by the 
hepatic artery. loses much of its total blood 
flow. The liver shrinkage that occurs in dogs 
(and also in rats. baboons. and humans 
[15.52)) and the wasting. hair loss. and brain 
damage that follow were aSCribed until the 
mid 1960s to the diminution of flow rather 
than the loss of exposure to the liver of any 
specific substancets) In the portal blood 
(53-56), This became known as the now hy-
pothesis of portal physiology. 
Although Welch accepted this false 
dogma and attnbuted auxiliary graft de-
struction to rejection al.one. he unwittingly 
had created an experimental model of great 
power. The pnnciple of the model was the 
coexistence of two livers In the same amma! 
with similar conditions except for the con-
tent of the blood delivered to the graft and 
native portal veins. When we repeated 
Welch's experiments in 1963 under immu-
nosuppression. auxiliary livers protected 
from rejection by azathioprine but deprived 
of splanchnic venous inflow shrank within 
a few days to a fraction of their original size 
(57). This acute atrophy was not seen in nor-
mallv vascularized orthotopic livers. The 
atrophy could be prevented in auxiliary liv-
ers if they were nourished with normal por-
tal blood: then. it afflicted the native liver 
that was deprived of its portal supply (58). 
Soon. nontransplant models were devel-
oped in which the animal's own liver was 
divided into two parts. each of which could 
be given the venous blood that came from 
different organs or different parts of the 
body (59.60) (Fig. 21-4). It was apparent 
that the healthy and hypertrophic liver frag-
ment with first access to the portal blood. 
particularly that returning from the upper 
abdominal viscera. was able to remove sub-
stance(s) so completely that lillie was left 
for the competing fragment which shriveled 
up (Fig. 21-5), From the outset. it was pos-
tulated that insulin was the most important. 
although not the only. liver-supporting sub-
stance (60-63), This conclusion was sup-
ported by later experiments in which the ef-
fect on the liver of removing the non hepatic 
visceral organs was tested (64.65). 
Meanwhile. infusion I!xperiments had 
heen performed showing that insulin. when 
injected alone into the tied-off central vein 
after portacaval shunt (Fig. 21-6). could 
prevent most of the consequences to the 
liver that were caused by the Eck tistula 
(66). As other liver growth factors of pan-
creatic. I!nteric. and non splanchnic origin 
have become available in recent years. they 
have been screened and evaluated for po-
tency with the Eck fistula model (67.6H). In 
this preparation. an active test substance 
prevents in the infused liver lobes the ex-
pected acute hepatocyte atrophy. organelle 
Jisruptlon. and fatty intiltrauon caused by 
depriving the liver of portal venous 
hlood-the companson 01 protected versus 
nonprotected hepatic tissue being similar to 
that in Figure 21-5. 
In addition to affecting the sile of hepato-
..:ytes. the most potent factors tested in the 
model shown In Figure 21-0 also promote 
I -
.. 
'* ':
i 
The C ontribmion of Transplantation 10 Gastroenrerolof?ic Knowledf?e 353 
PANCREATECTOMY 
Splanchnic division 
Fi2. 21 ... 1. Splanchnic division experiments. In these dogs. the right liver lobes rcceived venous 
return from the pancreatlcogastroduodenosplenic region. and the left liver lobes rcceived vcnous 
hlood from the intestines. A. nondiabetic dogs: B. alloxan-induced diabetic do!!s: C. uogs with total 
pancreatectomv. Reproduced with permiSSIon from Starzl TE et al.: The effect of diabele~ mellitus 
1m portal blood hepalolrophlc factors In dogs. Sur!! livnecol Obstel /.JO:549. 1975. 
proliferation-beginning with insulin (66) 
but also including the immunosuppressive 
agents cyclosporine (61}) and FK 506 (70) 
and the growth factors. insulin-like growth 
factor t IGF-m. transforming growth factor-
alpha tTGFa) and hepaLOcvte growth factor 
(HGF) IhM). By virtue of these develop-
ments. hepalotrophic physiology has be-
..:ome a .:onsistent countertheme of all rc-
~f!arch on the transplantation of splanchnic 
llrgans as well as a common ground shared 
hy liver transplantation. dinical ronal 
~hunt operations lall are variations of Eck' S 
tistulal. and the regeneration that follow~ 
hepaltc resection 115.71), In the ponal shunt 
tield. the new insight into portal hepato-
trophic physiology provIded an IOcenllve to 
llse ponal tlow-spanng procedures such as 
the Warren shunt 10 reference to complete 
ponal diversion for the treatment of portal 
hypertension (15). 
In contrast. the completely diverting por-
tacaval shunt has been used preferentially 
to palliate several inborn errors of metabo-
lism (15), The principle was to create with 
(omplete portal diversion a subtle kind of 
liver disease that inhibited the syntheSIS and 
accumulation of abnormal glycogen an pa-
tients with certain glycogen storage dis-
cases 17:), or alpha-l-antitrYPsln In patients 
with alpha-l-antllrypslO ddiciency In. 7.t), 
Because portal diverSIOn reduces the pro-
duclIon of cholesterol that ~annot be nor-
mallv ~atabolized in the disease of familial 
hypercholesterolemia. portacaval \hunt 
lllwered serum cholesterol in pallents with 
this diagnosis (75.76). The manufacture in 
the liver 01 many other substances also IS 
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LEFT RIGHT 
fig. 21-5. Hepatocyte shadows traced during histopathologic examination of liver biopSies from 
experiments shown in Figure 21-4A. These were later cut out on standard paper and weighed as an 
index of hepatocyte size. The right lobes with the large hepatic cells received venous hlood from the 
pancreas. stomach. duodenum. and spleen. The relatively shrunken left lobes with the small hepato-
cytes received intestinal blood. Reproduced with permission from Starzl TE et al.: Surg Gynecol 
Obstet 137:179. 1973. The ongm. hormonal nature. and action of hepatotrophic substances in ponal 
venous blood. 
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curtailed by portal diversion. but the conse-
quent adverse effects in patients with the 
metabolic diseases were superseded in sig-
nificance by the gain in control of the abnor-
mal or runaway metabolites. Eventually. It 
was shown that all three of the cited inborn 
errors. as well as many others. could be cor-
rected definitively by liver replacement (see 
subsequent section). When this occurred. 
the use of ponal diversion for metabolic 
purposes became obsolete. 
An additional ripple effect of research in 
transplantation was stimulated bv the refer-
ral for liver replacement of pailents with 
large but still localized liver neoplasms that 
were thought to be unresectable. As an al-
ternative to transplantation. we standard-
ized and popularized the previously danger-
ous operation of right trisegmentectomy 
(77) and introduced the new operation of left 
trisegmentectomv (extended left hcpatic lo-
bectomy) (78). 
IMMUNOSUPPRESSION 
While the gastroenterologic transplant 
()perations were being perfected. other de-
velopmcnts had raised hopes at their poten-
tial clinical application. The literature on 
these lkvelopments. which has been sum-
lllanzeJ elsewhere (79). bel!an with the 
demonstration bv Medawar In IY44 that re-
Jection IS an immunologIC event IMO.H II. The 
Jl!liberate weakening of the immune system 
with total bodv irradiation (l(!l. and conico-
"teroid thcrapy 183.84). and (much latcrl the 
thiopurlne compounds. o-mercaptopurine 
and azathioprine E~R-u9F ameliorated the re-
jection of skin grafts in rodents ami renal 
grafts in dogs. However. complete control 
'If rejection with a single agent was rarely 
achieved in animals without lethal side ef-
fects. This same thing was seen in discour-
aging clinical trials of renal transplantation 
(90-Y5). In the numerous clinical trials of 
kidne.v transplantation from January 1959 
through the autumn of 1962. there were only 
8 examples of survival for at least 5 
months-2 in Boston (90-92) and 6 in Paris 
(96.97). All except the last of these patients 
were treated primarily with total body irra-
diation: the final patient was the first to have 
long survival with azathioprine (92). 
This discouraging picture changed dra-
matically during 1962 and 1963 in Colorado. 
where the synergism of azathioprine and 
prednisone was known from animal investi-
gations IYHI. When these two drugs were 
used together from the outset in human kid-
ney transplant recipients. the results ex-
ceeded everyone's expectations 199.100) 
and precipitated a revolution in clinical 
transplantation. Success hinged. tirst. on 
the fact that acute rejection usually could 
be reversed with prednisone and. second. 
that the amount of drug treatment required 
to achieve stability of graft function often 
became less in time (1)9-102). 
The reversibility of rejection and change 
in host-graft relationship were eventually 
veritied wllh all other transplanted organs. 
heglnning with the livert 103.1041. Although 
Immunosuppression has improved. the cen-
t ral therapt!ullc Jllgma for whole organ 
transplantation that had emerged by 1Y63 
E~vKfllf has changcJ little In nearly .'0 
years. The dogma calls for daily treatment 
with one or two baseline drugs with further 
immune modulation by the highly duse-ma-
neuverable adrenal ~ortical "teroids tll 
whatever icvel is required (0 maintain stable 
graft funcllon (rable 11-/1. This means that 
.:very organ reCIpient goes through a mal 
rable 21-1 
Central Therapeutic Dogma 
Strategy 
1 Baseline therapy With one or two drugs 
') Seconaary adluStments With sterOids or 
antllympholo agents 
3. Case-te-case tnal (and potential errOr! of 
weanmg 
Baseline Agents 
1 Azathloprme 
2. Cyclephospnamrae 
J CyctosDonne 
ol FK 506 
Sites of Action 
DNA syntheSIS 
DNA syntheSIS 
IL·2 prOdUCtion 
IL-2 prOdUCtion 
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Table 21-2 
Principal Immunosuppressive Drug Regimens and Adjuncts· Used Clinically 
Year Described 
and Reported Used for GI 
Agents (Ref.) Place Deficiencies Organs 
Total body 1960 (90) Boston Ineffective. No 
irradiation dangerous 
Azathioprine 1962 (91) Boston Ineffective. No 
dangerous 
Azathioprine- 1963 (99) Denver Suboptimal Yes. liver 
steroids 
ThoracIc duct 1963 (105) Stockholm Nuisance: requires Yest. liver 
drainage as 20 to 30 days 
adjunct pretreatment 
Thymectomy as 1963 (106) Denver Unproven value Yes. rarely 
adJunct In 1963 
Splenectomy as 1963 (106) Denver No longer Yes. once 
adjunct necessary commonly 
tor liver 
ALG as adjunct 1966 (107) Denver Suboptimal Yes 
Cyclophosphamide 1970 (108) Denver No advantage Yes;. liver 
substitute for except for 
azathioprine patients with 
azathioprine 
toxicity 
Total lymphoid 1979 (109. 110) Palo Alto. Dangerous. Yes§. tor 
irradiation Minneapolis extensive liver 
preparation. not 
qUickly reverSible 
Cyclosponne 1978-1979 (111 ) Cambridge Suboptimal Yes 
Cyclosponne- 1980 (112) Denver Nephrotoxicity: Yes 
steroids reJection not 
always controlled 
FK506-sterolds 1989 (114) PittSburgh NephrotoxIcity: Yes 
reJection not 
always controlled 
• Until 1966. these were developed with kidney transplantation and applied for hvers. From 1966 onward. 
the liver increaSingly became the dominant test organ. 
t It was not realized until much later that pretreatment lor 3 to 4 weeks betore transplantation was a 
necessary condition for effective use of TOO 11131, 
; These trials were summarized many years later With at least 10 years follow-up for survIving pa-
tients (25). 
§ By Professor J, A Myburgh of Johannesourg. 
and potential e:rror experience as urugs are 
weaned to maintenance h!vels. 
The principal regimens useu clinically 
within this format over the ensuing 30 years 
are summarized in Table 2 I -2. ASide from 
the simplicity and the consequent case with 
which the therapeutic formula wuld be 
taught. it proved applicable to each new 
Jrug regimen or Immune modulallng tech-
ntque used clinically over the next 30 years 
( J 05-II-ll and to each ne:w organ. of Whldl 
the liver was the lirst alter the "Iuney am.l 
the intestine the mosl recent. 
The history of this remarkable phase: In 
transplantullon has heen told dsewhere 
1791. Even at the end of IlJo2. transplanta-
tion still seemed like a mirage. One ye:ar 
later. a Wild prolifcrallon of kiuney trans-
rlant centers had begun on both sides of the 
-\tlanuc. urive:n by knowle:dge of the e:tTI-
~ ; 
.. 
! 
f' 
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cacy of the "drug cocktail"' approach. of 
which the first example was the azathio-
prine-prednisone combination. Trials with 
the liver. the next vital organ beyond the 
kidney. had staned (115) and clinical kidney 
xenotransplantation with chimpanzee (116) 
and baboon ( 117) donors had been system-
atically tried with encouraging. although ul-
timately unsatisfactory. results. 
CLINICAL TRIALS OF LIVER 
TRANSPLANTATION 
Phase I: The Failed First Cases 
The prospect of establishing a forerunner 
kidney program in Denver 10 preparation for 
liver transplantation was the reason for mv 
move from Northwestern to the University 
of Colorado in late 1961 (I un. Now. the 
effectiveness of azathiopnne-prednisone 
cocktail for kidney grafting having been 
proved. a decision was taken to move on to 
the liver (115.119). The tirst recipient was a 
3-year-old boy with biliary atresia who had 
had mUltiple previous operations. The 
transplantation could not be completed be-
cause of a fatal hemorrhage from venous 
collaterals and an uncontrollable coagulopa-
thy. Even for a team that had been fully pre-
pared for technical vicissitudes by hundreds 
of animal operations. the exsanguinallon of 
this child was a terrible shock. 
Two more liver transplantations were 
carried out in the next 4 months. In both. 
the procedures seemed satisfactory. but the 
recipients died after 1:! and 7-1/2 davs. re-
spectively (115.119). The strategy of coagu-
lation control introduced after the death of 
I he !irst patient had a delaved back!ire in all 
\If the liver transplant recipients in whom it 
wus useu. During the lime when the livers 
were sewn in. the plastic external bvpasses 
wl!re uscJ to reroute venous blood around 
the area of the liver 10 the same wav as had 
neen worked out 10 Jogs. In the humans 
who wl!re being given drugs and bloou prou-
lIcts to promote clots. these dots formed in 
the hvpass tubing and pusseLi on 10 the 
lungs. There. they causeu abscesscs and 
\lIher lung damage which contributed to or 
caused ddaved death of all four of the pa-
llents who surVived the 101raoperallve pe-
riod 157.115l. A pall settled over the liver 
program. with a self-imposed moratorium 
that lasted more than 3 years. By this time. 
isolated attempts also were unsuccessful at 
the Brigham (120) and in France (l2l). 
When these first seven liver transplanta-
tions failed in three different centers (Table 
:! 1-3). pessimism settled in worldwide. The 
operation seemed too difficult to allow prac-
tical application. the methods of preserva-
tion were thought inadequate for an organ 
so seemingly sensitive to ischemic damage. 
and it began to be asked if immunosuppres-
sion available was considered too primitive 
to permit success. This last reservation was 
reinforced by the fact that truly chronic sur-
vival after liver replacement had never been 
achieved to this time in experimental an-
imals. 
Phase 2: Feasible But Impractical 
Therapy 
By the summer of 1967. these deficiencies 
had been at Icast partially rectitied by 3 
more years of laboratory effort. Many long-
term canine survivors had been obtained 
(103). some dogs having passed the 3-year 
postoperative mark. Better immunosup-
pression with the so-called triple drug ther-
apy wus now available. following the devel-
tlpment and tirst dinical trials in the world 
\11' antilymphocvte globulin I ALG) prepared 
from sensitized horses (107) and used 10 
~upplcment azathioprine and predntsone. 
Finall y. improved tcchniques of organ pres-
avation had been c.Jeveloped 112:!.1231. 
On July 13. 1967. a 1-112 year old child 
with a huge hepatoma was restored almost 
immediatcly from a moribund state to seem· 
ingly good health after liver replacement. 
More cases followed. The ripple ct'fect of 
'\uccessfully transplanting a vital organ 
tllher than the kidnev was far-reaching 
(114). If the liver. the most difticuit of all 
llrgans. could he transplanted. anything 
,cemed pOSSible. fhe smoldenng embers 10 
lllher specialty ccnters hurst mto !lames: 
tirst. with the heart transplantation 10 Cape-
lown hv Christlaan BarnarLi (December 
1%71. then With ~lltemptsDlf mtestlnal trans-
rlantatlon hy RicharLi Lillehet and William 
Kelly I Universl!v of Minnesota. 19071. and 
tinallv with the tirst successful lung trans-
rlnntatlon on Novemher f~K t%H Ihv F. 
Derom of LouvalO. Bdgtuml. 
-----,------
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Table 21-3 
The First 7 :\ttempts of Clinical Orthotopic Liver Transplantation 
Location Age Survival 
No. (Ref.) (Yr) Disease (Days) Main Cause of Death 
Denver (1 15) 3 Extrahepatic biliary 0 Hemorrhage 
atresia 
2 Denver (115) 48 Hepatocellular cancer. 22 Pulmonary emboli. 
cirrhosis sepsis 
3 Denver (115) 68 Duct cell carcinoma 7" 12 SepsIs. pulmonary 
emboli. 
gastrointestinal 
bleeding 
4 Denver (57) 52 Hepatocellular cancer. 6" 12 Pulmonary emboli. 
cirrhoSIS hepatic failure. 
pulmonary edema 
5 Boston (120) 58 Metastatic colon 11 PneumonItis. lIver 
carcinoma abscesses. hepatic 
failure 
6 Denver (57) 29 Hepatocellular cancer. 23 SepsIs. bile peritonitis. 
cirrhosIs 
7 Paris (121) 75 Metastatic colon 
carcinoma 
Most of these attempts failed early. and 
all of the patients eventually died. For the 
liver also. it was not a time of triumph. The 
child who became the tirst long-term survi-
vor after hepatic replacement died of recur-
rent cancer after 400 days. The maximum 
survival of the other six liver recipients 
treated between Julv 1%7 and March I%H 
was 2-1/2 years 125.124). For the next 12 
years. the I-year mortality after liver trans-
plantation never fell below 50% in cases that 
were accrued at the University of Colorado 
at the rate of about one per month. The terri-
ble losses were concentrated in the lirst 
postoperative months. After this. the life 
~urvival curve Ilattened. leaving a residual 
group of stable and remarkably well survi-
vors. Thiny II H%) of the lirst 170 patients in 
the consecutive series that started I March 
IlJ63 and ended in December IlJ79 lived 
more than a decade: 23 arc still alive alter 
13 to 23 years. All were treated with azathi-
oprine lOr cyclophosphamide). predmsone. 
and polvclonal ALG 1:!51. 
In the meanwhile. Professor Rov Caine 
at Cambridge Universltv I England) began 
dinical trials of liver transplantauon on May 
23. \%7. As 10 our earlier expenence. his 
tirst pallent e :<san!!ulOated {\ 251. :\ fcw 
hepatic failure 
0 Hemorrhage 
months later. Caine formed a collaboration 
that endured for more than two decades 
with the hepatologist. Professor Roger Wil-
liams. at Kings College Hospital in London. 
The Colorado and Cambridge-London 
teams wnunucd their dinical efforts 
through the years. In spite of frequent disap-
rOlOtments and many Iragic failures. The 
long survival of pauents In both senes was 
a testimonial for liver transplantation. but it 
was asked increasingly on both sides of the 
:\tlantic if such a small dividend could jus-
tify the prodigious effort that had brought 
liver transplantation this far (I 26). Other 
tcams established subsequent Iv in Hanno-
vcr (Rudolf Pichlmavr. 1lFT~F and Paris 
I Henri 13ismuth. 11J74) also reported the 
nearlv miraculous henetits 01 liver trans-
rlantallon when this treatment wa~ su~~cs~­
ful. but alwavs with the notation that the 
mortalit v was too great to allow II s practical 
llse. Liver transplantatIOn was a Icaslble but 
impractical operallon. 
Phase 3: The t:~Dclosporine/ch 506 Era 
The frustrallon ended when ~yDclosponne 
hecame avmlable cllnicallv tn IlJ79 (1111. 
hut onlv after this dru!! was ~ombtned wuh 
! -
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prednisone or lymphoid depletion in the 
tirst of the cyclosponne-based cocktails 
(112), Of our tirst 12 liver recIpients treated 
with cyclosporine and prednisone in the 
first IS months of 1980. II lived for more than 
a year 1127) and 7 are still alive more than 
12 years later. As the news was contirmed 
that I-year patient survival of at least 70% 
was readily achievable. new liver programs 
proliferated worldwide. When FK 506 was 
substituted for cyclosporine in 1999 (1141. 
t he I-year patient and liver graft survival 
rose another 15% in the Pittsburgh experi-
~nce (128), An improvement also was 
recorded in a multicenter European trial. By 
now. liver transplantation had become the 
accepted court of last appeal for almost all 
non-neoplastic liver diseases. and even for 
~clected patients with otherwise nonresect-
able hepatic malignancies. The principal 
limitation of the technology quicklv became 
the supply of organs to meet the burgeoning 
needs. 
Although the ascension of liver transplan-
tation was dominated by improvements in 
immunosuppression. other signiticant im-
provements occurred. including modified 
details of the operation Itself. The incidence 
llf biliary duct complications tobstructlon. 
tistula. and cholangitis). which had been 
more than 30c;r. (129), was reduced bv the 
lise of choledochocholedochostomv v.:llh a 
r-Illbe ~lcntK or If this was not feasible. hv 
choledocholejunostomv 10 a Roux limb 
(25). ~tanal!ement of coagulopathies was fa-
cilitated by the lise of the thromboelasta-
gram to follow the minute-to-mlnute clot-
lmg changes In the operallng room 
1115.130l. The systematIc usc of veno-ve-
nous bvpasses without anticoagulation also 
~reatlv uiminished the hcmorrhaces llf 
11Ightmare proportIons that were com-mon at 
lIne time t IJI)' 
t )RGA:'II PROCUREMENT 
lf~polhermia and Core Coolinc 
Sleps 111 the development of livcr graft 
rrocurement and preservation have heen 
Ic:w. However. these ~teps have had an Im-
rortance tar hevond their :lppilcallon tor 
Ii ver replacement. because the pnm:lples 
were applied equallv 10 olher whole orcans. 
rhc first "tep was core COOIIO\! 0\' tnlUSlon 
0f chilled lactated Ringer's solution into the 
portal vein (g) a laboratory technique 
promptly modified for use in clinical kidney 
transplantatIon (132). 
Today. core cooling is the tirst step in the 
preservation of all whole organ grafts. but 
in contrast to the original method. this is 
most often done by some variant of the in-
~itu technique originally developed at the 
University of Colorado to cool and continu-
ously perfuse cadaveric liver and kidney do-
nors before the acceptance of brain death 
-::onditions (133.134). Ackerman and Snell 
( 135) and Merkel and colleagues ( 136) sim-
plified the in-situ cooling of cadaveric kid-
neys with cold electrolyte solutions infused 
tnto the distal aorta. Finally. in-situ cold in-
fusion techniques were perfected that al-
lowed removal of all thoracic and abdominal 
(lrgans. including the liver. without Jeopar-
dizing any of the individual organs (137). 
\10ditications of this procedure have been 
made for unstable donors and even for do-
nors whose hearts have ceased to beat ( (38). 
In less than 5 years. multiple-organ procure-
ment. using techniques that are interchance-
able not only from city to city but from 
country to country. had become standard-
Ized in all parts of the world. 
The technique i" versatile. A complete 
midline abdominal and thoracic incision is 
made. The aorta at the diaphragm IS cnClr-
-.:Ied so Ihat it can be crossclamped when 
I he core cooling is be~unK The distal aona 
f~ used as an entry site for the tluid infUSion. 
By coordination of the tluid infusion and the 
crossclamping of the !!reat vessels and bv 
dissection and ligation of appropriate arte-
nal branches. the cold infusate can be made 
10 go selectively to the organs I including the 
liven that are to be transplanted. The portal 
\'\!In of the liver also is infused after a cat he-
Icr IS placed into it through the spleniC veIn 
,lr other malor trthutarv. Core cooling of the 
I horaclc or~ans I' accomplished with the 
,ame principles (1.171. Alter the chilled or-
o:ans have been removed. suhsequent pres-
ervatIOn mav he hv "Imple rcfn!!eratlon. or 
hv -.llphisllcatcd methods III continuous 
[1ertuslOn. 
I"IDICATIONS FOR LIVER 
roAkpmiy~qA TION 
Because the potentlallv ~ullable candl-
Jates 10r ilver tr:.msplantatlon OUlnumoer 
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Table 21-4 
Generic Listing of Liver Diseases 
Treatable by Hepatic Transplantation 
Disease 
Parenchymal 
Postnecrotic cirrhosis 
Alcoholic cirrhosIs 
Acute liver failure 
Budd-Chian syndrome 
Congenital hepatic fibrosis 
Cystic fibrosIs 
Neonatal hepatitis 
Hepatic trauma 
Cholestatic 
Biliary atresia 
Primary biliary cirrhoSIS 
Sclerosing cholangitis 
Secondary biliary cirrhosIs 
Familial cholestasls 
Inborn errors of metabolism 
Tumors 
Benign 
Primary malignant 
Metastatic 
the available organs by 3 to 1. the selection 
of appropriate recipients from such a large 
pool requires highly individualized assess-
ment. By 19M9. the list of benign diseases 
treatable by transplantatIOn had become so 
long that it was increasingly given in broad 
.:ategones such as cholestatic or parenchy-
mal disease (Table 21-4\. The simpliticatlon 
made it easy (0 lose sight of the fact Ihat 
nearly 100 distinct diseases have been 
treated with liver transplantation. including 
more than 20 in the broad category of chole-
static disorders. Because products of he-
patic synthesis permanently retain the origi-
nal metabolic speciticity of the donor after 
transplantauon 1139.140), liver transplanta-
tion is a deCISive way to treat many liver-
based or liver-mlluenced inborn t!rrors of 
metabolism ITable 21-5'. 
Diseases that precluded transplantallon :\ 
llr 10 years ago. ~uch as alcoholic CirrhOSIS. 
.Ire no longer absolute contramdicallons. In 
addition. s.:arnng lrom multiple upper ab-
Jommal operations and pnor portal-svs-
tt!mlc shunts that at one time would have 
ruled out liver transplantation art! no longer 
IIvernding deterrents In any maJOr ct!nier. 
Ex.tenslve thrombOSIS of the portal and su-
penor mesentenc vems which prevlOuslv 
made liver transplantation difficult or im-
possible has been almost eliminated as 
a contraindication to attempted liver 
transplantation by the use of vein grafts 
<141-145). 
Inflexible age proscriptions at either the 
upper or lower range have been dropped_ 
The shortage of appropriate-sized donors 
for very small pediatric recipients was 
greatly ameliorated by the use of liver frag-
ments. The tirst known reduced liver graft 
operation was performed in Denver in 1975 
(146) but was not reported until long after 
the landmark descriptions of this technique 
by Henri Bismuth and Didier Houssin of 
Paris tl~TF and the team of Rudolf Pichl-
mayr and Christoph Hroelsch of Hannover 
( 14M), 
The use of conventional liver transplanta-
tion to treat otherwise nonresectable pri-
mary or metastatic hepatic cancers has re-
sulted in a very high rate of recurrence 
(139). Nevertheless. the use of liver trans-
plantation to treat cancer is stitt being inves-
tigated by many transplantation teams. 
almost invariably in combination with adju-
vant chemotherapy or other experimental 
treatment protocols. Certain kinds of neo-
plasms have a better prognosis than others. 
A crucial condition of candidacy involves 
ruling out the possibility that the tumor has 
"pread beyond the liver. 
A radical cxtenslOn of this wncept IS the 
removal of organ clusters to en bloc diver. 
pancreas. spleen. "wmach. Juodenum. 
proXimal jejunum. and right colon I to treat 
I.!xtenslve sarcomas and carCinoid tumors of 
the pancreas or duodenum with liver metas-
tases. bile duct carcinomas with liver metas-
tases. and hepatomas lhat had invaded the 
Juodenum and colon ( 14tJI. The eXCised or-
gans have been replaced with hepatopan-
.:reatlcoduodenal grafts t :-.ee Fig. 21 -I e'. or 
in some ':.Ises bv the liver alont!. 
CLINICAL TRIALS OF f~qbpql~Ai 
rRANSPLANTATION f~ COMPOSITE 
'·.SCERAL (;RAFTS OR ALONE 
Composite (;raHs 
Function tor more than .1 half \'\':411" III a 
.:adavt!nc Inlesllne was nOI ;I.:comphshed 
lIntll I'lX7 (1:'0.1511. III November III that 
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Table 21-5 
Inborn Errors of Metabolism Treated with Liver Transplantation-Most of the Patients 
Were in UniversIty of Colorado-University of Pittsburgh Series. Follow-up to January 
1989 (139). 
Longest Associated 
Disease Explanation of Disease Survival Liver Disease 
Cl1Antitrypsin deficiency Structural abnormality of the 13 yr CirrhosIS 
protease Inhibitor synthesized in 
liver 
Wilsons disease Abnormal biliary copper excretion. 16.5 yr CirrhosIs 
decreased copper binding to 
ceruloplasmin. and copper 
accumulation an tissues; 
autosomal recessIve gene 
mappecl to chromosome 13 
TyrOSinemia Fumaroylacetoacetate hydrolase 7.5 yr CirrhoSIS. 
deficIency hepatoma 
Type I glycogen Glucose-6-phosphatase deficiency 7 yr Glycogen 
storage disease storage. 
fibrosIs. 
tumors 
Type IV glycogen Amylo-l : 4.1 : 6-transglucosidase 4.5 yr CirrhosIs 
storage disease (branching enzyme) defect 
Cystic fibrosIs Unknown: pancellular disease. liver 4.5 yr CirrhoSIS 
often affected 
Niemann-Pick disease Sphingomyelinase deficiency. 2 yr (died) None 
sphingomyelin storage 
Sea-blue histiocyte Unknown. neurovlsceral lipochrome 7 yr CirrhosIs 
syndrome storage 
Erythropoietic HepatiC ferrochelatase deficIency. 1.5 yr CirrhoSIS 
protoporphyna ?overproductlve ot 
protoporphYrin bv erythropoIetIc 
tissues 
Crigler-NajJar syndrome Glucuronyl transferase deficiency 4 yr None 
Type 1 hyperoxaluna Peroxisomal alanine: glyoxylate 8 mo. None 
aminotransferase deficiency 
Urea cycle enzyme Ornithine carbamoyltransferase 8 mo. None 
deficiency (3 types) deficiency 
C protem deficiency Defective C protein synthesIs 2.25 yr None 
Familial Low-density lipoprotein receptor 6 yr None 
hypercholesterolemia deficiency. low-density lipoprotein 
overprocluctlon 
Hemophilia A Factor VIII deficiency 4 yr CirrhoSIS. a 
complication 
of blOOd 
component 
therapy 
HemOPhilia B Factor IX deflclencv 6 mo CirrhOSIS. a 
complication 
of blooa 
component 
therapy 
j. 
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vear. the recipient of a multivisceral graft 
~ho was treated with cyclosporine. predni-
sone. and the antilymphoid agent. OKT3. 
survived for 192 days before dying of a B 
cell lymphoma (46). Several subsequent re-
cipients of the full multi visceral graft (see 
Fig. 21-1. center) are alive after as long as 
17 months under treatment with FK 506 
(36.152), 
A variant procedure in which only the 
liver and small bowel are retained (see Fig. 
21-lc) was described by Grant et al. (153) of 
London. Ontario. This operation has been 
particularly useful in patients with the short 
gut syndrome who developed liver failure 
after prolonged hyperalimentation (36). 
Using FK 506. \3 (76.5l!C) of 17 patients in 
the Pittsburgh series of liver-tntestinal 
grafts are alive after 5 to 31 months-all but 
one liberated from total parenteral hyperali-
mentation tTPN) (36.152), 
Intestinal Transplantation Alone 
As recently as late 1991. some workers in 
the field believed that the protection to the 
intestine afforded by the concomitant trans-
plantation of the liver from the same donor 
(see previous text) was sufficiently great to 
justify combined liver and intestinal trans-
plantation even when only a technically 
simpler intestinal transplant was needed. 
Enthusiasm for this Jracoman strategy 
hegan to fade with the successful transplan-
tation in March 1999 of a cadaveriC small 
intestine by Goulet et al. (35) of Paris. and 
of an ileal segment from a living rdated 
donor by Deitz of Kiel. Germany (154), 
These were isolated straws in the wind. 
The routine survival of cadaveric intestinal 
recipients [hen became possible in Pitts-
burgh under immunosuppression with FK 
~MSK where the results have been betler with 
isolated intestinal transplantation than with 
I!ither the multivisceral operation or liS liv-
I!r-intesllne vanant 136.152), Eight of I} such 
recipients are alive. ~f!veral after 1 to 2 
vears-dll but one bem!! TPN -free. The ex-
pected release of FK 506 for general use In 
the near future IS cert:un [0 stimulate rapid 
further development 01 the Intestmal trans-
r1antallon tield. 
\letabolic Interactions 
~onammunologic factors .:an inlluence 
the success or failure or' abdommal orl,!an 
grafts. Normally. the venous effluent from 
all of the nonhepatic splanchnic organs con-
tributes to the portal blood supply. ensuring 
the liver of first-pass exposure to the intes-
tinal nutrients. and the so-called portal hep-
atotrophic substances. of which insulin is 
the most important. 
When partial multivisceral grafts such as 
the liver-intestine are used in recipients 
whose pancreas and other upper abdominal 
organs are retained. it is preferable to direct 
the venous effluent from the residual host 
organs into the portal circulation of the new 
liver. Otherwise. subtle injury of the liver 
typical of. although less severe than. that 
caused by Eck fistula. .:an be produced. 
Similarly. when the intestme is transplanted 
alone. the ideal route of venous return is 
through the liver. However. the inabilitv for 
technical reasons to drain intestinal return 
into the host liver has not caused severe he-
patic complications in a small number of our 
human recipients (36). 
MECHANISM OF GRAFT 
ACCEPTANCE 
Throughout the modern historv of trans-
plantation. it has not been known how grafts 
were able. with the aid of immunosuppres-
~ionK to weather the initial attack by the re-
.:ipient Immune ~vstemK and later to merge 
half-forgotten into the host. Study of the 
gastrointestinal organs and their recipients 
has provided unique Insights Into this pro-
.:ess ( 155.156>. In 1%9. t he Ii ver became the 
tirst transplanted organ to be recognized as 
having a composite (chimeric) ~[ructureK It 
was noted that the Kuptfcr cdls and other 
tissue leukocytes hecame predominantly re-
cipient-phenotype within 100 days after 
transplantation while [he hepatocvtes per-
manentlv retamed their donor speciticity. 
.. \t the time and long afterward. this trans-
formation was assumed to he unaque to the 
hepatic allograft. 
However. 22 years l'lter. lirSl an rat 
models (157)' and then In humans (15K), it 
was realiL.ed that the same proK:e~s occurred 
in all sIH.:.:essfullv transplanted intestines. 
The epithelium urlhe hllWcl remamed that 
(If the donor. \\ hcreas (he I \'mphoid. den-
dritic and other leulwclites of reCIpient ori-
;!In qUlcklv hecame the oommunt cells in the 
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lamma propria. Pever's patches. and mes-
enteric nodes. Subsequent studies of the 
kidnev and thoracIc organs made it obvIous 
that all whole-organ grafts underwent a sim-
ilar transformation that differed onlv quanti-
tatively from organ to organ. The number 
of substituted tissue leukocytes ranged from 
large in the case of the liver to small in or-
gans like the kidney and heart. 
What remained to be determmed was 
the fate of the leukocytes vacating the 
grafts. The answers were provided in the 
"'prlng and summer of 191J2 by the longest 
\urvivors of kidnev and liver transplanta-
tion t 155.156.159.1601. Samples were taken 
trom the transplanted organ as well as from 
the patient's own skin. Ivmph nodes. and 
'lther tissues. After special ~faming proce-
Jures t Immunostaming or sex identlticatlon 
;lller Iluorescence in-silu hyhridizatlon,. the 
tissues were exammed under the micro-
... cope In see if the individual cells that made 
them up had come from the organ donor. 
Ihe recipient's own bodv. or both. Alterna-
lively. the donor and recipient contributions 
10 anv specimen could be separated by polv-
merase chain reactlons ( .. DN A fingerprint-
ing") techniques. 
Within minutes after restoring the blood 
... upply of anv whole organ transplant. myn-
ads of sessile but potentially migratory leu-
kocytes that are part of the normal structure 
of all organs left the graft and migrated all 
over the recipient while similar recipient 
cells took their place in the transplant with-
l)ut disturbing the highly specialized donor 
parenchymal cells (Fig. :! \-7L The relo-
cated donor and recipient leukocytes 
learned to live in harmony. provided they 
were given sufficient protection during their 
nesting by immunosuppressive drugs. The 
... ame process applied to the intestine and all 
whole organs. In this new context. the drugs 
could be viewed as tranie directors. allow-
ing movement of the white cells in both di-
rections (to and from the graft! but prevent-
ing the immune destruction that is the 
normal purpose of this tranie. 
It is not known yet how the two sets of 
white cells-a small popUlation of predomi-
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nantlv dendritic celis from the donated 
organ and a large one that is in essence the 
entire recipient immune system of the pa-
tient-reach a "truce." This is so complete 
in some cases that immunosuppression can 
be stopped. particularly after liver trans-
plantation and less constantly with other or-
gans. Such a stable biologic state can be in-
duced more easily by the liver than by other 
transplanted organs because of the liver's 
higher content of the critical missionary leu-
kocytes. This was thought to be the expla-
nation for the protection afforded the intes-
tine by a concomitantly transplanted liver 
(38.39). 
While still incomplete. this much infor-
mation already provides a tool with which 
to shape future strategies ( 156.159). The mi-
gratory cells can be puritied from the bone 
marrow or spleen of a donor and then in-
fused to improve the "acceptability" ofvar-
ious organs from that specific donor includ-
ing those taken from an animal for use in 
humans as xenogratis. The cell migration 
and mixed chimerism phenomena make 
comprehensible the unexpected inability of 
donor-recipient HLA matching to accu-
rately predict the outcome of whole organ 
transplantation ( 1611. As a result of the mu-
tual cell engagement. neither the new organ 
nor its new host remains the same as at the 
time of the matching tests. 
WHOLE-ORGAN 
XENOTRANSPLANT A TlON 
When organs are transplanted from a 
significantly disparate species. the lirst 
immunologic hurdle is that of preformed 
xenospecitic antibodies. which qUlcklv de-
vascularize the graft and exclude it from re-
-:Ipient circulatIOn by Jamagmg its nlood 
vessels (1621. If this barner can be ~ur­
mounted. the process of xenograft a..:-:ep-
lance involves the same bidirectional ..:dl 
migration and consequent systemic chimer-
ism as with allotransplantation t I (3). This 
means that successful clinical .\cnotrans-
rlantallon must he Visualized alan!! the 
~ame lines 01 donor-reCIpient cellular mIgra-
tion and repopulation as with aliogralt ac-
ceptance. 
SUMMARY 
Over a period of 38 years. it has become 
possible to successfullv transplant individ-
ual intra-abdominal viscera or combinations 
of these organs. The consequences have 
been. first. the acquisition of new informa-
tion about the metabolic interrelations that 
the visceral organs have in disease or 
health: second. the addition of several 
transplant and nontransplant procedures to 
the treatment armamentarium for G I dis-
eases: and third. the development of a more 
profound understanding of the means by 
which all whole organ grafts are .. ac-
cepted ... 
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